GaiaCell develops therapies based on tumor-infiltrating lymphocytes (TILs) as a personalized immunotherapeutic approach for the treatment of solid tumors. Our development is focused on clinical feasibility, process reproducibility, and long-term applicability in real-world clinical settings.
TILs (tumor-infiltrating lymphocytes) are immune cells naturally present within tumor tissue and capable of recognizing tumor antigens. TIL therapy is based on isolating these cells from the tumor, expanding them ex vivo, and re-administering them to the patient to enhance the anti-tumor immune response. TIL therapies represent an important approach, particularly for solid tumors, where other forms of immunotherapy often fail to achieve sufficient clinical efficacy.
Treatment of solid tumors remains a major clinical challenge due to:
TIL therapies address these limitations by using the patient’s own, tumor-reactive T cells, enabling a more targeted and biologically grounded therapeutic approach.
We place particular emphasis on balancing the biological efficacy of TIL cells with the practical feasibility of the manufacturing process. Development of TIL therapies at GaiaCell is based on a structured translational approach that integrates:
TIL therapies offer:
Due to these characteristics, TIL therapies represent an important component of future combination immunotherapy strategies.
Ti so:
TIL therapies leverage immune cells that are already proven to recognize tumors, reducing the need for artificial redirection of the immune response.
Our development targets indications with significant unmet clinical needs, where personalized cell-based approaches represent a realistic therapeutic opportunity.
Processes are designed with clinical use, scalability, and long-term integration into clinical practice in mind.
The GaiaCell TIL program is developed within a preclinical and translational framework, with a clear focus on understanding biological mechanisms, optimizing manufacturing processes, and preparing for clinical validation. Details regarding protocols, selection strategies, and expansion methods remain part of a protected development environment and are subject to professional discussion within collaborations.
TIL therapies represent a natural complement to GaiaCell’s CAR-T and exosome development programs. Together, they form a comprehensive portfolio of advanced cell and cell-derived therapeutic platforms designed for diverse clinical challenges and indications.
Open to Development Partnerships
GaiaCell seeks collaborations in the areas of:
We build partnerships based on professional dialogue, shared development goals, and a long-term vision for advanced immunotherapeutic solutions.